Last reviewed · How we verify
Meletios A. Dimopoulos — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- European Myeloma Network B.V. · 1 shared drug class
- Millennium Pharmaceuticals, Inc. · 1 shared drug class
- National Cancer Institute (NCI) · 1 shared drug class
- PETHEMA Foundation · 1 shared drug class
- Pfizer · 1 shared drug class
- Shilpa · 1 shared drug class
- Telik · 1 shared drug class
- University of Arkansas · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Meletios A. Dimopoulos:
- Meletios A. Dimopoulos pipeline updates — RSS
- Meletios A. Dimopoulos pipeline updates — Atom
- Meletios A. Dimopoulos pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Meletios A. Dimopoulos — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/meletios-a-dimopoulos. Accessed 2026-05-17.